Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% an...

Descripción completa

Detalles Bibliográficos
Autores principales: Arashiro, Takeshi, Arima, Yuzo, Kuramochi, Jin, Muraoka, Hirokazu, Sato, Akihiro, Chubachi, Kumi, Yanai, Atsushi, Arioka, Hiroko, Uehara, Yuki, Ihara, Genei, Kato, Yasuyuki, Yanagisawa, Naoki, Ueda, Akihiro, Kato, Hideaki, Oka, Hideaki, Nishida, Yusuke, Nidaira, Yuki, Asami, Takahiro, Jinta, Torahiko, Nakamura, Akira, Oba, Kunihiro, Taniyama, Daisuke, Yamamoto, Kei, Tanaka, Katsushi, Ueshima, Kankuro, Fuwa, Tetsuji, Stucky, Ashley, Suzuki, Tadaki, Smith, Chris, Hibberd, Martin, Ariyoshi, Koya, Suzuki, Motoi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284337/
https://www.ncbi.nlm.nih.gov/pubmed/37351451
http://dx.doi.org/10.1093/ofid/ofad240
_version_ 1785061379717201920
author Arashiro, Takeshi
Arima, Yuzo
Kuramochi, Jin
Muraoka, Hirokazu
Sato, Akihiro
Chubachi, Kumi
Yanai, Atsushi
Arioka, Hiroko
Uehara, Yuki
Ihara, Genei
Kato, Yasuyuki
Yanagisawa, Naoki
Ueda, Akihiro
Kato, Hideaki
Oka, Hideaki
Nishida, Yusuke
Nidaira, Yuki
Asami, Takahiro
Jinta, Torahiko
Nakamura, Akira
Oba, Kunihiro
Taniyama, Daisuke
Yamamoto, Kei
Tanaka, Katsushi
Ueshima, Kankuro
Fuwa, Tetsuji
Stucky, Ashley
Suzuki, Tadaki
Smith, Chris
Hibberd, Martin
Ariyoshi, Koya
Suzuki, Motoi
author_facet Arashiro, Takeshi
Arima, Yuzo
Kuramochi, Jin
Muraoka, Hirokazu
Sato, Akihiro
Chubachi, Kumi
Yanai, Atsushi
Arioka, Hiroko
Uehara, Yuki
Ihara, Genei
Kato, Yasuyuki
Yanagisawa, Naoki
Ueda, Akihiro
Kato, Hideaki
Oka, Hideaki
Nishida, Yusuke
Nidaira, Yuki
Asami, Takahiro
Jinta, Torahiko
Nakamura, Akira
Oba, Kunihiro
Taniyama, Daisuke
Yamamoto, Kei
Tanaka, Katsushi
Ueshima, Kankuro
Fuwa, Tetsuji
Stucky, Ashley
Suzuki, Tadaki
Smith, Chris
Hibberd, Martin
Ariyoshi, Koya
Suzuki, Motoi
author_sort Arashiro, Takeshi
collection PubMed
description In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
format Online
Article
Text
id pubmed-10284337
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102843372023-06-22 Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan Arashiro, Takeshi Arima, Yuzo Kuramochi, Jin Muraoka, Hirokazu Sato, Akihiro Chubachi, Kumi Yanai, Atsushi Arioka, Hiroko Uehara, Yuki Ihara, Genei Kato, Yasuyuki Yanagisawa, Naoki Ueda, Akihiro Kato, Hideaki Oka, Hideaki Nishida, Yusuke Nidaira, Yuki Asami, Takahiro Jinta, Torahiko Nakamura, Akira Oba, Kunihiro Taniyama, Daisuke Yamamoto, Kei Tanaka, Katsushi Ueshima, Kankuro Fuwa, Tetsuji Stucky, Ashley Suzuki, Tadaki Smith, Chris Hibberd, Martin Ariyoshi, Koya Suzuki, Motoi Open Forum Infect Dis Brief Report In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). Oxford University Press 2023-05-03 /pmc/articles/PMC10284337/ /pubmed/37351451 http://dx.doi.org/10.1093/ofid/ofad240 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Arashiro, Takeshi
Arima, Yuzo
Kuramochi, Jin
Muraoka, Hirokazu
Sato, Akihiro
Chubachi, Kumi
Yanai, Atsushi
Arioka, Hiroko
Uehara, Yuki
Ihara, Genei
Kato, Yasuyuki
Yanagisawa, Naoki
Ueda, Akihiro
Kato, Hideaki
Oka, Hideaki
Nishida, Yusuke
Nidaira, Yuki
Asami, Takahiro
Jinta, Torahiko
Nakamura, Akira
Oba, Kunihiro
Taniyama, Daisuke
Yamamoto, Kei
Tanaka, Katsushi
Ueshima, Kankuro
Fuwa, Tetsuji
Stucky, Ashley
Suzuki, Tadaki
Smith, Chris
Hibberd, Martin
Ariyoshi, Koya
Suzuki, Motoi
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title_full Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title_fullStr Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title_full_unstemmed Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title_short Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
title_sort effectiveness of ba.1- and ba.4/ba. 5-containing bivalent covid-19 mrna vaccines against symptomatic sars-cov-2 infection during the ba.5-dominant period in japan
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284337/
https://www.ncbi.nlm.nih.gov/pubmed/37351451
http://dx.doi.org/10.1093/ofid/ofad240
work_keys_str_mv AT arashirotakeshi effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT arimayuzo effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT kuramochijin effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT muraokahirokazu effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT satoakihiro effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT chubachikumi effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT yanaiatsushi effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT ariokahiroko effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT ueharayuki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT iharagenei effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT katoyasuyuki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT yanagisawanaoki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT uedaakihiro effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT katohideaki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT okahideaki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT nishidayusuke effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT nidairayuki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT asamitakahiro effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT jintatorahiko effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT nakamuraakira effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT obakunihiro effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT taniyamadaisuke effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT yamamotokei effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT tanakakatsushi effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT ueshimakankuro effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT fuwatetsuji effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT stuckyashley effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT suzukitadaki effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT smithchris effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT hibberdmartin effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT ariyoshikoya effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan
AT suzukimotoi effectivenessofba1andba4ba5containingbivalentcovid19mrnavaccinesagainstsymptomaticsarscov2infectionduringtheba5dominantperiodinjapan

Ejemplares similares